Figure 2
Figure 2. MiR-181b expression values discriminate samples of patients with stable versus progressive disease. Relative expression of the mature miR-181b in serial time points from patients with CLL with a progressive (violet dots) or stable (yellow dots) disease in the training (A) and validation (B) set. The bars indicate the mean values and the errors. P value is the result of the Mann-Whitney test. Patients with (violet lines) or without (yellow lines) the properties, defined on the base of miR-181b expression values, are indicated in the training (C) or validation (D) set. The ending points are showed with either a circle for patients with IGHV ≤ 98% or a cross for patients with IGHV ≥ 98%. Squares denote patients with unknown values. P value is the result of the Fisher exact test. MiR-181b relative expression is determined by stem-loop real-time qPCR. Each sample of data was normalized to the endogenous reference RNU44 with the use of 2−Δct method.

MiR-181b expression values discriminate samples of patients with stable versus progressive disease. Relative expression of the mature miR-181b in serial time points from patients with CLL with a progressive (violet dots) or stable (yellow dots) disease in the training (A) and validation (B) set. The bars indicate the mean values and the errors. P value is the result of the Mann-Whitney test. Patients with (violet lines) or without (yellow lines) the properties, defined on the base of miR-181b expression values, are indicated in the training (C) or validation (D) set. The ending points are showed with either a circle for patients with IGHV ≤ 98% or a cross for patients with IGHV ≥ 98%. Squares denote patients with unknown values. P value is the result of the Fisher exact test. MiR-181b relative expression is determined by stem-loop real-time qPCR. Each sample of data was normalized to the endogenous reference RNU44 with the use of 2−Δct method.

Close Modal

or Create an Account

Close Modal
Close Modal